Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) Director Richard A. Heyman sold 1,270 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $19.99, for a total value of $25,387.30. Following the completion of the transaction, the director now owns 137,155 shares of the company’s stock, valued at approximately $2,741,728.45. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Enliven Therapeutics Stock Down 5.4 %
NASDAQ:ELVN opened at $19.94 on Tuesday. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $26.00. The stock has a market capitalization of $821.53 million, a PE ratio of -9.10 and a beta of 1.06. The stock’s 50-day moving average price is $16.88 and its 200-day moving average price is $14.25.
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.09. Sell-side analysts expect that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Enliven Therapeutics
Analyst Ratings Changes
Separately, Mizuho started coverage on Enliven Therapeutics in a research note on Tuesday, April 9th. They issued a “buy” rating and a $34.00 target price for the company.
View Our Latest Stock Report on ELVN
About Enliven Therapeutics
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Stories
- Five stocks we like better than Enliven Therapeutics
- 3 REITs to Buy and Hold for the Long Term
- The Charles Schwab Company Can Hit New Highs
- How to Read Stock Charts for Beginners
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- The 3 Best Retail Stocks to Shop for in August
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.